HGA
VRTX icon

Hobbs Group Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Hobbs Group Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,871
Closed -$733K – 179
2025
Q3 		$733K Sell
1,871
-737
-28% -$308K 0.23% 76
2025
Q2 		$1.16M Sell
2,608
-599
-19% -$276K 0.4% 49
2025
Q1 		$1.55M Sell
3,207
-144
-4% -$67.1K 0.59% 32
2024
Q4 		$1.35M Sell
3,351
-100
-3% -$46.4K 0.51% 40
2024
Q3 		$1.6M Sell
3,451
-20
-0.6% -$9.61K 0.58% 27
2024
Q2 		$1.63M Buy
+3,471
New +$1.51M 0.62% 31
2023
Q4 		$1.17M Buy
+2,873
New +$1.06M 0.52% 33

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Hobbs Group Advisors's VRTX Position: Q4 2025 in Review

Hobbs Group Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q4 2025, closing a stake of 1,871 shares — an estimated $733K sold.

Hobbs Group Advisors first reported a position in VRTX in Q4 2023 and held it in 7 quarters. The position peaked at $1.63M in Q2 2024. 1,670 funds tracked by Wall St. Rank hold VRTX as of Q4 2025.

  • Hobbs Group Advisors reported no remaining Vertex Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Hobbs Group Advisors sold 1,871 Vertex Pharmaceuticals shares in Q4 2025, an estimated $733K.
  • Hobbs Group Advisors first reported a position in Vertex Pharmaceuticals in Q4 2023 and held it in 7 quarters.
  • Hobbs Group Advisors's Vertex Pharmaceuticals position peaked at $1.63M in Q2 2024.
  • 1,670 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2025.

Based on Hobbs Group Advisors's 13F filing for Q4 2025, filed 28 Jan 2026.